Compare First Citizens BancShares Inc (FCNCA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Merck & Co., Inc. — how do they compare? First Citizens BancShares Inc trades at $2,173.73 (market cap $23.76B), while Merck & Co., Inc. trades at $128.35 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 12.8× First Citizens BancShares Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| FCNCA | MRK | |
|---|---|---|
Market Cap | $23.76B | $305.29B |
Sector | Sector/Thematic | Health |
52-Week High | $2.20K | $129.52 |
52-Week Low | $1.64K | $77.60 |
Dividend Yield | 0.41% | 2.75% |
Enterprise Value | — | $348.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,133.72, up 3.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a trailing P/E of 11.94 and consistent earnings beats, including a Q1 2026 EPS of $44.86 versus $39.56 expected. Recent strategic moves include plans to retire the Silicon Valley Bank brand and expand commercial banking capabilities in Q4 2026.
The outlook is supported by solid profitability with a 24.35% net income margin and a shareholder-friendly dividend. Key risks include margin pressure and credit risk exposure from the legacy SVB portfolio. Analyst consensus is cautious with an 81.82% hold rating, though the consensus price target of $2,320 suggests modest upside from current levels.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
